Eli Lilly will shell out $2.4 billion to acquire genetic medicine developer Orna Therapeutics and has committed up to $8.85 billion to launch a seventh collaboration with Innovent Biologics. Both ...
Comprehensive residue-level mapping of amyloid-beta recognition reveals how sequence variants, post-translational modifications, and aggregation state shape antibody specificity, thereby guiding ...
Objective: To evaluate the synergistic immunological protection of exosomal T-cell epitope vaccine and antibody-inducing vaccine against SARS-CoV-2 in highly humanized mice. Results: The combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results